Explore

Trendline Trendline
Gilead Sciences to Showcase New HIV Research at AIDS 2026, Highlighting Prevention and Treatment Advances

Gilead Sciences to Showcase New HIV Research at AIDS 2026, Highlighting Prevention and Treatment Advances

Gilead Sciences to Showcase New HIV Research at AIDS 2026, Highlighting Prevention and Treatment Advances
Rapid Read Rapid Read
Gilead Sciences to Present New HIV Research at AIDS 2026 Conference

Gilead Sciences to Present New HIV Research at AIDS 2026 Conference

Gilead Sciences, Inc. is set to present new findings at the 26th International AIDS Conference in Rio de Janeiro. The company will showcase data from its HIV research, focusing on prevention, treatment, and potential cures. Highlights include long-term data from the PURPOSE trials, demonstrating the efficacy and safety of lenacapavir for pre-exposure prophylaxis (PrEP). Gilead will also present results from the ISLEND trials, which explore a novel weekly HIV treatment regimen. The conference will feature discussions on expanding global access to HIV prevention and treatment, particularly in regions with high unmet needs.
Rapid Read Rapid Read
Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials

Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials

Gilead Sciences and Merck have announced promising results from their Phase 3 ISLEND-1 and ISLEND-2 trials, which evaluated a once-weekly oral HIV treatment regimen combining islatravir and lenacapavir. The trials demonstrated that this regimen effectively maintained virologic suppression in adults with HIV who switched from daily antiretroviral therapy. The ISLEND-1 trial showed that none of the participants who switched to the once-weekly regimen had HIV-1 RNA levels of 50 copies/mL or more at Week 48, compared to 0.3% of those who remained on the daily regimen BIKTARVY. Similarly, the ISLEND-2 trial found that 0.3% of participants on the once-weekly regimen had HIV-1 RNA levels of 50 copies/mL or more, compared to 1.3% on standard daily treatments. The safety profile of the once-weekly regimen was comparable to existing treatments, with no new safety concerns identified.
Trendline Trendline
Terra Innovatum's Nuclear Power Deal to Support Latin American Data Centres

Terra Innovatum's Nuclear Power Deal to Support Latin American Data Centres

Terra Innovatum's Nuclear Power Deal to Support Latin American Data Centres
Trendline Trendline
Terra Innovatum's Micro-Modular Nuclear Reactors to Power Latin American Data Centres

Terra Innovatum's Micro-Modular Nuclear Reactors to Power Latin American Data Centres

Terra Innovatum's Micro-Modular Nuclear Reactors to Power Latin American Data Centres
Trendline Trendline
Gilead Sciences to Present New HIV Research at AIDS 2026 Conference

Gilead Sciences to Present New HIV Research at AIDS 2026 Conference

Gilead Sciences to Present New HIV Research at AIDS 2026 Conference
Reuters Reuters
Fewer children got US-backed HIV treatment after aid cuts, study finds

Fewer children got US-backed HIV treatment after aid cuts, study finds

By Jennifer Rigby and Vincent Mumo Nzilani LONDON/NAIROBI, July 21 (Reuters) - Around 77,000 fewer children worldwide received HIV treatment supported by the U.S. in the year to October 2025 than in the previous fiscal year, according to a study that found declines after the Trump administration's
Trendline Trendline
Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials

Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials

Gilead and Merck's Once-Weekly HIV Treatment Shows Promise in Phase 3 Trials
AP News AP News
US actions harm global efforts to prevent and treat HIV in dozens of countries, new report says

US actions harm global efforts to prevent and treat HIV in dozens of countries, new report says

A new report says the Trump administration’s disruptions to a global AIDS relief program have forced organizations to close clinics, lay off staff and cut services, seriously impeding efforts to prevent and treat the disease in dozens of countries
Rapid Read Rapid Read
Terra Innovatum and Waiken ILW to Deploy Microreactors for Data Centers in Latin America

Terra Innovatum and Waiken ILW to Deploy Microreactors for Data Centers in Latin America

Terra Innovatum, a micro-modular nuclear reactor developer, has announced a partnership with Waiken ILW to deploy its SOLO micro-modular reactor platform for data center infrastructure in Latin America and Brazil. The initiative aims to provide reliable, clean energy solutions for data centers operated by DIRECTV Latin America and SKY Brasil. The agreement marks Terra Innovatum's first commercial deployment in Latin America, reflecting growing demand for standardized, factory-built micro-modular nuclear power.
Trendline Trendline
Anitta Collaborates with Brazilian Music Icons in 'Equilibrium II'

Anitta Collaborates with Brazilian Music Icons in 'Equilibrium II'

Anitta Collaborates with Brazilian Music Icons in 'Equilibrium II'
Trendline Trendline
Terra Innovatum to Deploy Microreactors for Data Center Infrastructure in Latin America

Terra Innovatum to Deploy Microreactors for Data Center Infrastructure in Latin America

Terra Innovatum to Deploy Microreactors for Data Center Infrastructure in Latin America